BillionToOne

BillionToOne focuses on innovative molecular diagnostics, utilizing their proprietary QCT technology to detect and measure DNA fragments at a single base-pair level. Their key products include the UNITY Screen, a non-invasive prenatal test that identifies fetal risk for aneuploidies and recessive conditions from a maternal blood sample, and the Northstar liquid biopsy assays, which aid in cancer therapy selection and monitoring by analyzing tumor DNA. Their mission is to enhance healthcare accessibility and precision through cutting-edge molecular testing techniques.